Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-08 09:07 am Purchase |
2025-06-30 | 13G | Catalyst Biosciences, Inc. CBIO |
FMR LLC | 1,414,190 10.200% |
1,414,190 (New Position) |
Filing History |
| 2025-06-23 6:32 pm Purchase |
2025-06-13 | 13D | Catalyst Biosciences, Inc. CBIO |
Fairmount Funds Management LLC | 3,124,220 19.990% |
3,124,220 (New Position) |
Filing History |
| 2025-06-23 4:30 pm Purchase |
2025-06-13 | 13G | Catalyst Biosciences, Inc. CBIO |
Venrock Healthcare Capital Partners III, L.P. | 1,391,196 9.900% |
1,391,196 (New Position) |
Filing History |
| 2025-06-20 4:05 pm Purchase |
2025-06-20 | 13D | Catalyst Biosciences, Inc. CBIO |
Adage Capital Management, L.P. | 50,912 0.370% |
50,912 (New Position) |
Filing History |
| 2025-02-14 6:38 pm Sale |
2024-12-31 | 13G | GlycoMimetics, Inc. GLYC |
RA Capital Management, L.P. | 0 0.000% |
-63,830 (Position Closed) |
Filing History |
| 2024-11-27 2:22 pm Purchase |
2024-11-25 | 13G | GlycoMimetics, Inc. GLYC |
Logos Global Management LP | 50,000 7.800% |
50,000 (New Position) |
Filing History |
| 2024-11-12 4:30 pm Sale |
2024-09-30 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 19,651 3.000% |
-33,234 (-62.84%) |
Filing History |
| 2024-11-06 5:41 pm Purchase |
2024-10-30 | 13G | GlycoMimetics, Inc. GLYC |
RA Capital Management, L.P. | 63,830 9.900% |
63,830 (New Position) |
Filing History |
| 2024-11-04 4:26 pm Purchase |
2024-10-29 | 13D | GlycoMimetics, Inc. GLYC |
Adage Capital Management, L.P. | 50,912 7.900% |
50,912 (New Position) |
Filing History |
| 2024-11-04 2:01 pm Sale |
2024-10-30 | 13G | GlycoMimetics, Inc. GLYC |
Weinstein Benjamin | 500 0.100% |
-33,539 (-98.53%) |
Filing History |
| 2024-08-15 5:01 pm Sale |
2024-08-13 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 52,885 8.200% |
-33,006 (-38.43%) |
Filing History |
| 2024-08-14 4:13 pm Purchase |
2024-08-09 | 13G | GlycoMimetics, Inc. GLYC |
Weinstein Benjamin | 34,039 5.300% |
34,039 (New Position) |
Filing History |
| 2024-07-29 7:24 pm Purchase |
2024-07-25 | 13G | GlycoMimetics, Inc. GLYC |
Invus Public Equities, L.P. | 85,891 13.300% |
85,891 (New Position) |
Filing History |
| 2024-05-08 5:06 pm Sale |
2024-05-06 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 21,819 5.000% |
-18,261 (-45.56%) |
Filing History |
| 2024-02-29 7:28 pm Sale |
2024-02-06 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 40,080 6.200% |
-7,139 (-15.12%) |
Filing History |
| 2024-02-12 4:48 pm Sale |
2024-02-06 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 47,219 7.300% |
-43,895 (-48.18%) |
Filing History |
| 2024-02-09 5:03 pm Purchase |
2023-12-31 | 13G | GlycoMimetics, Inc. GLYC |
Artal Participations S.a r.l | 85,891 13.300% |
20,153 (+30.66%) |
Filing History |
| 2024-01-29 4:31 pm Unchanged |
2023-03-29 | 13G | GlycoMimetics, Inc. GLYC |
BIOTECHNOLOGY VALUE FUND L P | 95,443 14.800% |
0 (Unchanged) |
Filing History |
| 2023-02-13 5:18 pm Purchase |
2023-02-09 | 13G | GlycoMimetics, Inc. GLYC |
Artal Participations S.a r.l | 65,738 12.500% |
65,738 (New Position) |
Filing History |
| 2023-02-10 5:23 pm Purchase |
2023-01-26 | 13D | GlycoMimetics, Inc. GLYC |
New Enterprise Associates 10, Limited Partnership | 49,675 9.500% |
49,675 (New Position) |
Filing History |